BULN2
MCID: BLM002
MIFTS: 61

Bulimia Nervosa (BULN2)

Categories: Mental diseases, Neuronal diseases

Aliases & Classifications for Bulimia Nervosa

MalaCards integrated aliases for Bulimia Nervosa:

Name: Bulimia Nervosa 58 12 77 56 45 15 17 74
Bulimia Nervosa, Susceptibility to 58 13
Bulimia Nervosa 2 76 30
Bulimia 45 74
Bulimia Nervosa, Susceptibility to, Type 2 41
Binge Eating Disorder 74
Hyperorexia Nervosa 12
Buln2 76
Buln 58
Bn 58

Characteristics:

OMIM:

58
Inheritance:
multifactorial


HPO:

33
bulimia nervosa:
Inheritance multifactorial inheritance


Classifications:



External Ids:

Disease Ontology 12 DOID:12129
OMIM 58 607499
NCIt 51 C97162
SNOMED-CT 69 78004001
ICD10 34 F50.2
MedGen 43 C1853220

Summaries for Bulimia Nervosa

OMIM : 58 Bulimia nervosa (BN) is a psychiatric disorder characterized by episodes of binge-eating (eating an unusually large amount of food in a discrete period of time and feeling out of control), compensatory behavior (e.g., self-induced vomiting or laxative abuse), and over-concern with weight and shape. Eating disorders such as bulimia nervosa are complex disorders that can be influenced by many genes. (607499)

MalaCards based summary : Bulimia Nervosa, also known as bulimia nervosa, susceptibility to, is related to depression and eating disorder, and has symptoms including salt craving, decrease in appetite and symptoms. An important gene associated with Bulimia Nervosa is BULN (Bulimia Nervosa, Susceptibility To), and among its related pathways/superpathways are Peptide ligand-binding receptors and cAMP signaling pathway. The drugs Topiramate and Dopamine have been mentioned in the context of this disorder. Affiliated tissues include brain, testes and skin, and related phenotypes are bulimia and behavior/neurological

Disease Ontology : 12 An eating disorder characterized by the restraining of food intake for a period of time followed by an over intake or binging period that results in feelings of guilt and low self-esteem.

UniProtKB/Swiss-Prot : 76 Bulimia nervosa 2: A psychiatric disorder characterized by eating an unusually large amount of food in a short period of time, followed by inappropriate acts (purging) to avert weight gain. Compensatory behavior includes self-induced vomiting, laxative abuse, and excessive exercise.

Wikipedia : 77 Bulimia nervosa, also known as simply bulimia, is an eating disorder characterized by binge eating... more...

Related Diseases for Bulimia Nervosa

Diseases related to Bulimia Nervosa via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 184)
# Related Disease Score Top Affiliating Genes
1 depression 31.1 BDNF HTR2A SLC6A4
2 eating disorder 30.9 BDNF CCK COMT GHRL LEP MC4R
3 alexithymia 30.4 COMT SLC6A4
4 pathological gambling 30.4 HTR2A SLC6A4
5 anorexia nervosa 30.4 BDNF CCK COMT GHRL HTR2A LEP
6 atypical depressive disorder 30.3 HTR2A SLC6A4
7 dysthymic disorder 30.2 HTR2A SLC6A4
8 gastroesophageal reflux 30.2 CCK GHRL PYY
9 substance dependence 30.2 BDNF HTR1B SLC6A4
10 alcohol abuse 30.1 BDNF HTR2A SLC6A4
11 personality disorder 30.1 BDNF COMT HTR1B HTR2A SLC6A4
12 gastroparesis 30.0 CCK GHRL HTR3A
13 borderline personality disorder 29.9 BDNF COMT HTR1B HTR2A SLC6A4
14 disease of mental health 29.7 BDNF CCK COMT HTR2A SLC6A4
15 irritable bowel syndrome 29.7 CCK HTR3A PYY SLC6A4
16 antisocial personality disorder 29.7 COMT HTR1B SLC6A4
17 anxiety 29.6 BDNF COMT HTR2A HTR3A NPY SLC6A4
18 social phobia 29.6 CCK HTR3A SLC6A4
19 bipolar disorder 29.5 BDNF COMT HTR2A SLC6A4
20 panic disorder 29.4 CCK COMT HTR2A HTR3A SLC6A4
21 endogenous depression 29.3 BDNF HTR2A NPY SLC6A4
22 obsessive-compulsive disorder 29.2 BDNF COMT HTR1B HTR2A HTR3A SLC6A4
23 attention deficit-hyperactivity disorder 29.1 BDNF COMT HTR1B HTR2A NPY SLC6A4
24 substance abuse 29.1 BDNF COMT HTR1B NPY SLC6A4
25 body mass index quantitative trait locus 11 29.0 CCK GHRL LEP MC4R NPY PYY
26 morbid obesity 29.0 CCK GHRL LEP MC4R PYY
27 generalized anxiety disorder 28.7 BDNF COMT HTR2A HTR3A SLC6A4
28 mood disorder 28.7 BDNF COMT HTR1B HTR2A NPY SLC6A4
29 major depressive disorder 28.3 BDNF COMT HTR1B HTR2A HTR3A NPY
30 alcohol dependence 28.2 BDNF CCK COMT GHRL HTR1B HTR2A
31 schizophrenia 27.2 BDNF CCK COMT HTR1B HTR2A HTR3A
32 ataxia - hypogonadism - choroidal dystrophy 11.1
33 mallory-weiss syndrome 11.1
34 bowenoid papulosis 10.4
35 body mass index quantitative trait locus 1 10.3
36 gastric dilatation 10.3
37 duodenogastric reflux 10.3 CCK PYY
38 stereotypic movement disorder 10.3 CCK NPY
39 pol iii-related leukodystrophies 10.3
40 pancreatic steatorrhea 10.3 CCK GHRL
41 diabetes mellitus 10.2
42 x-linked recessive intellectual disability-macrocephaly-ciliary dysfunction syndrome 10.2
43 psychosexual disorder 10.2 HTR2A SLC6A4
44 alcoholic psychosis 10.2 HTR2A SLC6A4
45 intermittent explosive disorder 10.2 NPY SLC6A4
46 periodic limb movement disorder 10.2 HTR2A SLC6A4
47 early-onset schizophrenia 10.2 BDNF HTR2A
48 placental choriocarcinoma 10.2 LEP SLC6A4
49 gastrointestinal system disease 10.2 CCK GHRL PYY
50 schizophrenia 5 10.1 HTR2A HTR3A

Graphical network of the top 20 diseases related to Bulimia Nervosa:



Diseases related to Bulimia Nervosa

Symptoms & Phenotypes for Bulimia Nervosa

Human phenotypes related to Bulimia Nervosa:

33
# Description HPO Frequency HPO Source Accession
1 bulimia 33 HP:0100739

Symptoms via clinical synopsis from OMIM:

58
Neurologic Behavioral Psychiatric Manifestations:
recurrent episodes of binge eating
recurrent inappropriate conpensatory behavior to prevent weight gain, including self-induced vomiting, laxative or diuretic abuse, fasting, excessive exercise
overconcern with weight and body shape
feelings of guilt associated with episodes

Clinical features from OMIM:

607499

UMLS symptoms related to Bulimia Nervosa:


salt craving, decrease in appetite, symptoms

MGI Mouse Phenotypes related to Bulimia Nervosa:

47
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 10 BDNF COMT GHRL HTR1B HTR2A HTR3A
2 endocrine/exocrine gland MP:0005379 9.81 BDNF CCK COMT GHRL HTR1B HTR2A
3 adipose tissue MP:0005375 9.8 GHRL HTR1B LEP MC4R NPY PYY
4 homeostasis/metabolism MP:0005376 9.65 BDNF CCK COMT GHRL HTR3A LEP
5 nervous system MP:0003631 9.28 BDNF CCK COMT HTR3A LEP MC4R

Drugs & Therapeutics for Bulimia Nervosa

Drugs for Bulimia Nervosa (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 182)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Topiramate Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 97240-79-4 5284627
2
Dopamine Approved Phase 4,Phase 2,Phase 3,Not Applicable 62-31-7, 51-61-6 681
3
Fluoxetine Approved, Vet_approved Phase 4,Not Applicable 54910-89-3 3386
4
Amphetamine Approved, Illicit, Investigational Phase 4,Phase 2 300-62-9 3007 5826
5
Dextroamphetamine Approved, Illicit Phase 4,Phase 2 51-64-9 5826
6
Liraglutide Approved Phase 4,Phase 3 204656-20-2 44147092
7
Orlistat Approved, Investigational Phase 4,Not Applicable 96829-58-2 3034010
8
Memantine Approved, Investigational Phase 4,Not Applicable 19982-08-2 4054
9
Norepinephrine Approved Phase 4,Not Applicable 51-41-2 439260
10
Risperidone Approved, Investigational Phase 4 106266-06-2 5073
11 Raclopride Investigational Phase 4 84225-95-6
12 Hypoglycemic Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
13 Anticonvulsants Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
14 Neurotransmitter Uptake Inhibitors Phase 4,Phase 2,Phase 3,Not Applicable
15 Neurotransmitter Agents Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
16 Dopamine Uptake Inhibitors Phase 4,Phase 2,Phase 3,Not Applicable
17 Peripheral Nervous System Agents Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
18 Central Nervous System Stimulants Phase 4,Phase 3,Phase 2,Phase 1
19 Dopamine Agents Phase 4,Phase 2,Phase 3,Not Applicable
20 Serotonin Uptake Inhibitors Phase 4,Phase 2,Not Applicable
21 Cytochrome P-450 CYP2D6 Inhibitors Phase 4,Phase 2,Phase 3,Not Applicable
22 Cytochrome P-450 Enzyme Inhibitors Phase 4,Phase 2,Phase 3,Not Applicable
23 Serotonin Receptor Agonists Phase 4,Phase 2
24 Antidepressive Agents Phase 4,Phase 2,Phase 3,Not Applicable
25 Antidepressive Agents, Second-Generation Phase 4,Phase 2,Phase 3,Not Applicable
26 Psychotropic Drugs Phase 4,Phase 2,Phase 3,Not Applicable
27 Serotonin Agents Phase 4,Phase 2,Not Applicable
28 Dopamine Antagonists Phase 4
29 Sympathomimetics Phase 4,Phase 2,Phase 1,Not Applicable
30 Adrenergic Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
31 Tranquilizing Agents Phase 4,Phase 3,Phase 2,Not Applicable
32 Antipsychotic Agents Phase 4,Phase 3,Not Applicable
33 Central Nervous System Depressants Phase 4,Phase 2,Phase 3,Not Applicable
34 Autonomic Agents Phase 4,Phase 2,Phase 1,Not Applicable
35 Appetite Depressants Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
36 Anti-Obesity Agents Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
37 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 3,Phase 2,Not Applicable
38 Hormones Phase 4,Phase 3,Phase 2,Not Applicable
39 Hormone Antagonists Phase 4,Phase 3,Phase 2,Not Applicable
40 Incretins Phase 4,Phase 3
41 Atomoxetine Hydrochloride Phase 4,Phase 3
42 Lipid Regulating Agents Phase 4,Phase 2,Not Applicable
43 Excitatory Amino Acid Antagonists Phase 4,Not Applicable
44 Excitatory Amino Acids Phase 4,Not Applicable
45 Antiparkinson Agents Phase 4,Phase 3,Not Applicable
46 Serotonin and Noradrenaline Reuptake Inhibitors Phase 4
47 Analgesics Phase 4
48 Duloxetine Hydrochloride Phase 4
49 Serotonin Antagonists Phase 4,Phase 2,Not Applicable
50
Serotonin Investigational, Nutraceutical Phase 4,Phase 2,Not Applicable 50-67-9 5202

Interventional clinical trials:

(show top 50) (show all 240)
# Name Status NCT ID Phase Drugs
1 Topiramate Augmentation in Bulimia Nervosa Partial Responders Withdrawn NCT00988481 Phase 4 Topiramate
2 Evaluation of the Efficacy of Serotoninergic Antidepressants in Bulimia Nervosa, According to Brain Serotonin Profile Determined by Positron Emission Tomography With [18F] MPPF. Recruiting NCT02359513 Phase 4 Antidepressants;Positron Emission Tomography (PET)
3 Monoamine Contributions to Neurocircuitry in Eating Disorders Completed NCT02020408 Phase 4 [11C]raclopride;[11C]DASB;amphetamine
4 Treatment of Binge Eating in Obese Patients in Primary Care Completed NCT00537810 Phase 4 Sibutramine;Placebo
5 Influence of Appetite Related Hormones in Binge Eating Behaviour Among the Overweight and Obese Completed NCT01739049 Phase 4 Liraglutide
6 Fluoxetine to Prevent Relapse and Enhance Psychological Recovery in Women With Anorexia Nervosa Completed NCT00288574 Phase 4 Fluoxetine;Placebo
7 Atomoxetine in the Treatment of Binge Eating Disorder Completed NCT00327834 Phase 4 atomoxetine
8 Study of Behavioral Weight Loss Therapy for Obesity and Binge Eating in Monolingual Hispanic Persons Completed NCT00516919 Phase 4 Xenical + behavioral intervention
9 An Open-Label Trial of Memantine in the Treatment of Binge Eating Disorder Completed NCT00330655 Phase 4 memantine
10 Study of Duloxetine vs Placebo in Treatment of Binge Eating Disorder With Depression Completed NCT00607789 Phase 4 Duloxetine;Placebo
11 A Double-blind, Placebo Controlled Trial of Risperidone for the Treatment of Anorexia Nervosa Completed NCT00140426 Phase 4 Risperidone;Placebo
12 The Efficacy of Readiness and Motivation Therapy in Individuals With Anorexia Nervosa and Bulimia Nervosa Unknown status NCT00220662 Phase 3
13 Improving Patient Outcome in Group Therapy for Eating Disorders Unknown status NCT01693237 Phase 2, Phase 3
14 Clinical Trial on Binge Eating Disorder, Treatment With Naloxone Spray Unknown status NCT01567670 Phase 2, Phase 3 Naloxone;naloxone placebo
15 N-acetylcysteine in the Treatment of Bulimia Nervosa Terminated NCT01033149 Phase 3 N-acetylcysteine
16 N-acetylcysteine in Bulimia Nervosa Terminated NCT01131572 Phase 2, Phase 3 N-acetylcysteine NAC
17 Binge Eating Liraglutide Intervention Recruiting NCT03279731 Phase 3 Liraglutide (Saxenda) 6Mg/Ml Inj Pen 3Ml;Placebo
18 Sodium Oxybate in the Treatment of Binge Eating Disorder Completed NCT00514995 Phase 2, Phase 3 Sodium Oxybate
19 Acamprosate in the Treatment of Binge-Eating Disorder Completed NCT00511940 Phase 2, Phase 3 acamprosate
20 An Efficacy and Tolerability Study for Topiramate in Obese Patients With Binge Eating Disorder. Completed NCT00307619 Phase 3 topiramate
21 Efficacy and Mechanisms of Naltrexone+Bupropion for Binge Eating Disorder Recruiting NCT03539900 Phase 2, Phase 3 Bupropion Hydrochloride, Naltrexone Hydrochoride Drug Combination
22 Behavioral and Pharmacologic Treatment of Binge Eating and Obesity: Specialist Treatment Enrolling by invitation NCT03063606 Phase 2, Phase 3 NB Medication (on-going from acute treatment)
23 Behavioral and Pharmacologic Treatment of Binge Eating and Obesity: Maintenance Therapy Enrolling by invitation NCT03047005 Phase 2, Phase 3 NB medication (Naltrexone Bupropion combination)
24 Behavioral and Pharmacologic Treatment of Binge Eating and Obesity: Acute Treatment Recruiting NCT03045341 Phase 2, Phase 3 NB medication (Naltrexone Bupropion combination)
25 Dasotraline Binge Eating Disorder Extension Study Active, not recruiting NCT02684279 Phase 3 Dasotraline
26 Dasotraline Binge Eating Disorder Study Completed NCT02564588 Phase 2, Phase 3 Dasotraline;Placebo
27 Deficits in Emotion Regulation Skills as a Maintaining Factor in Binge Eating Disorder Completed NCT03717493 Phase 2, Phase 3
28 Evaluate the Maintenance of Efficacy of SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder Completed NCT02009163 Phase 3 Lisdexamfetamine dimesylate
29 A Study to Evaluate a Drug (Dasotraline) on the Safety, Effectiveness and How Well the Body Tolerates it, in Adults With Moderate to Severe Binge Eating Disorder Completed NCT03107026 Phase 3 dasotraline 4mg;dasotraline 6mg;Placebo
30 SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder Completed NCT01718509 Phase 3 SPD489 (Lisdexamfetamine dimesylate);Placebo
31 SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder Completed NCT01718483 Phase 3 SPD489 (Lisdexamfetamine dimesylate);Placebo
32 Open Label Extension in Adults With Binge Eating Disorder (BED) Completed NCT01657019 Phase 3 Lisdexamfetamine dimesylate
33 Efficacy Study of Lisdexamfetamine to Treat Binge Eating Disorder Completed NCT01090713 Phase 3 lisdexamfetamine;Placebo control
34 Armodafinil in Binge Eating Disorder (BED) Completed NCT01010789 Phase 3 Armodafinil;Armodafinil;Matching placebo
35 A Study to Examine the Efficacy and Safety of Meridia® (Sibutramine Hydrochloride) in Binge-Eating Disorder Completed NCT00402584 Phase 3 sibutramine
36 Pramipexole for Binge Eating Disorder Withdrawn NCT01106053 Phase 3 Pramipexole
37 Craving, Binge Eating and Obesity Completed NCT00414167 Phase 2, Phase 3 bupropion
38 Meditation-Based Treatment for Binge Eating Disorder Completed NCT00032760 Phase 2, Phase 3
39 Lamotrigine in the Treatment of Binge Eating Disorder Associated With Obesity Completed NCT00277641 Phase 3 Lamotrigine;placebo
40 Zonegran in the Treatment of Binge Eating Disorder Associated With Obesity Completed NCT00221442 Phase 3 Zonegran;sugar pill
41 A Study of the Effectiveness and Safety of Topiramate in the Treatment of Moderate to Severe Binge-eating Disorder Associated With Obesity Completed NCT00210808 Phase 2, Phase 3 topiramate
42 Efficacy of Atomoxetine on Psychosocial Function of Children and Adolescents With Attention-Deficit/Hyperactivity Disorder (ADHD) Completed NCT00320528 Phase 3 atomoxetine
43 Lisdexamfetamine in Binge Eating Disorder (BED): fMRI Effects Unknown status NCT02659488 Phase 2 Lisdexamfetamine
44 The Effect of Electroacupuncture on Obesity Unknown status NCT01102075 Phase 2
45 Lisdexamfetamine for Adults With Bulimia Nervosa Recruiting NCT03397446 Phase 2 Lisdexamfetamine dimesylate
46 Effectiveness of Antibiotic Treatment for Reducing Binge Eating and Improving Digestive Function in Bulimia Nervosa Completed NCT00304187 Phase 2 Erythromycin;Placebo
47 Family Therapy for Adolescent Bulimia Nervosa Completed NCT00518843 Phase 2
48 Cognitive Behavioral Therapy to Treat Bulimia Nervosa in Adolescents Completed NCT00522769 Phase 1, Phase 2
49 Focused Versus Enhanced Cognitive Behavioral Therapy for Treating Women With Bulimia Nervosa Completed NCT00494858 Phase 2
50 Co-Feedback Action of Growth Hormone, PP and PYY on Ghrelin in Bulimia Enrolling by invitation NCT03338387 Phase 2 Acipimox;Placebo

Search NIH Clinical Center for Bulimia Nervosa

Inferred drug relations via UMLS 74 / NDF-RT 52 :


Cochrane evidence based reviews: bulimia nervosa

Genetic Tests for Bulimia Nervosa

Genetic tests related to Bulimia Nervosa:

# Genetic test Affiliating Genes
1 Bulimia Nervosa 2 30

Anatomical Context for Bulimia Nervosa

MalaCards organs/tissues related to Bulimia Nervosa:

42
Brain, Testes, Skin, Liver, Cortex, Heart, Thyroid

Publications for Bulimia Nervosa

Articles related to Bulimia Nervosa:

(show top 50) (show all 1969)
# Title Authors Year
1
Impact of comorbid borderline personality disorder on inpatient treatment for bulimia nervosa: analysis of routine data. ( 30680217 )
2019
2
Disgust, impulsivity and depressive dimensions in subjects at risk for bulimia nervosa and/or binge eating disorder. ( 30522004 )
2019
3
Efficacy of psychotherapy for bulimia nervosa and binge-eating disorder on self-esteem improvement: Meta-analysis. ( 30623519 )
2019
4
Sex Differences in Adolescent Anorexia and Bulimia Nervosa: Beyond the Signs and Symptoms. ( 30637488 )
2019
5
Altered functional connectivity in binge eating disorder and bulimia nervosa: A resting-state fMRI study. ( 30644179 )
2019
6
Patients' views on a new treatment for Bulimia nervosa and binge eating disorder combining physical exercise and dietary therapy (the PED-t). A qualitative study. ( 30664397 )
2019
7
Approach bias modification training in bulimia nervosa and binge-eating disorder: A pilot randomized controlled trial. ( 30689229 )
2019
8
Socio-demographic and psychological risk factors for suicidal behavior among individuals with anorexia and bulimia nervosa: A systematic review. ( 30699859 )
2019
9
A test of the DSM-5 severity specifier for bulimia nervosa in adolescents: Can we anticipate clinical treatment outcomes? ( 30701572 )
2019
10
Recent Research on Bulimia Nervosa. ( 30704637 )
2019
11
Internet-based aftercare for women with bulimia nervosa following inpatient treatment: The role of adherence. ( 30723692 )
2019
12
Rituals and preoccupations associated with bulimia nervosa in adolescents: Does motivation to change matter? ( 30734406 )
2019
13
Increased Functional Connectivity Between Ventral Attention and Default Mode Networks in Adolescents With Bulimia Nervosa. ( 30738550 )
2019
14
Psychiatric comorbidity as a risk factor for the mortality of people with bulimia nervosa. ( 30756148 )
2019
15
Paucisymptomatic pulmonary and right ear tuberculosis in young woman suffering from anorexia and bulimia nervosa. ( 30766647 )
2019
16
Using internet-based self-help to bridge waiting time for face-to-face outpatient treatment for Bulimia Nervosa, Binge Eating Disorder and related disorders: Study protocol of a randomized controlled trial. ( 30775262 )
2019
17
Impact of telephone prompts on the adherence to an Internet-based aftercare program for women with bulimia nervosa: A secondary analysis of data from a randomized controlled trial. ( 30792960 )
2019
18
Altered anticipation and processing of aversive interoceptive experience among women remitted from bulimia nervosa. ( 30840983 )
2019
19
Treating bulimia nervosa in the context of gender dysphoria using 10-session cognitive behavior therapy. ( 30843609 )
2019
20
Subcortical Shape Abnormalities in Bulimia Nervosa. ( 30846367 )
2019
21
Negative affect, dietary restriction, and food choice in bulimia nervosa. ( 30903862 )
2019
22
Brief Strategic Therapy for Bulimia Nervosa and Binge Eating Disorder: A Clinical and Research Protocol. ( 30906269 )
2019
23
Resolving bulimia nervosa using an innovative neural therapy approach: two case reports. ( 29445463 )
2018
24
Treatments for bulimia nervosa: a network meta-analysis. ( 29729686 )
2018
25
Would glucagon-like peptide-1 receptor agonists have efficacy in binge eating disorder and bulimia nervosa? A review of the current literature. ( 29407005 )
2018
26
The role of maternal anorexia nervosa and bulimia nervosa before and during pregnancy in early childhood wheezing: Findings from the NINFEA birth cohort study. ( 29722053 )
2018
27
Effects of intranasal oxytocin on the attentional bias to emotional stimuli in patients with bulimia nervosa. ( 29529522 )
2018
28
Medical Complications In Anorexia And Bulimia Nervosa. ( 29848283 )
2018
29
Sleep profile in anorexia and bulimia nervosa female patients. ( 29890462 )
2018
30
Testing the relative associations of different components of dietary restraint on psychological functioning in anorexia nervosa and bulimia nervosa. ( 29807122 )
2018
31
Comorbid depressive symptoms and self-esteem improve after either cognitive-behavioural therapy or family-based treatment for adolescent bulimia nervosa. ( 29446174 )
2018
32
Differential Diagnoses of Food-Related Gastrointestinal Symptoms in Patients with Anorexia Nervosa and Bulimia Nervosa: A Review of Literature. ( 29498331 )
2018
33
A single-arm pilot study of guided self-help treatment based cognitive behavioral therapy for bulimia nervosa in Japanese clinical settings. ( 29695260 )
2018
34
Satiation deficits and binge eating: Probing differences between bulimia nervosa and purging disorder using an ad lib test meal. ( 29654850 )
2018
35
How Does Food Taste in Anorexia and Bulimia Nervosa? A Protocol for a Quasi-Experimental, Cross-Sectional Design to Investigate Taste Aversion or Increased Hedonic Valence of Food in Eating Disorders. ( 29593595 )
2018
36
Validation of the Inventory of Interpersonal Problems (IIP-64): a comparison of Swedish female outpatients with anorexia nervosa or bulimia nervosa and controls. ( 29703121 )
2018
37
Feeling fat in eating disorders: Testing the unique relationships between feeling fat and measures of disordered eating in anorexia nervosa and bulimia nervosa. ( 29653375 )
2018
38
Adherence to the Mediterranean dietary pattern and incidence of anorexia and bulimia nervosa in women: The SUN cohort. ( 29704863 )
2018
39
Variation in reproductive outcomes of women with histories of bulimia nervosa, anorexia nervosa, or eating disorder not otherwise specified relative to the general population and closest-aged sisters. ( 29331083 )
2018
40
Altered cortical thickness and attentional deficits in adolescent girls and women with bulimia nervosa. ( 29688871 )
2018
41
Core psychopathology in anorexia nervosa and bulimia nervosa: A network analysis. ( 29693747 )
2018
42
The Impact of Alexithymia on Emotion Dysregulation in Anorexia Nervosa and Bulimia Nervosa over Time. ( 29266572 )
2018
43
Neuroimaging in bulimia nervosa and binge eating disorder: a systematic review. ( 29468065 )
2018
44
Body composition and physical fitness in women with bulimia nervosa or binge-eating disorder. ( 29473191 )
2018
45
Emotional dysregulation and attachment dimensions in female patients with bulimia nervosa. ( 29546861 )
2018
46
Affect and worry during a checking episode: A comparison of individuals with symptoms of obsessive-compulsive disorder, anorexia nervosa, bulimia nervosa, body dysmorphic disorder, illness anxiety disorder, and panic disorder. ( 30599438 )
2018
47
Gender differences in eating disorder psychopathology across DSM-5 severity categories of anorexia nervosa and bulimia nervosa. ( 30193008 )
2018
48
Time trends in healthcare-detected incidence of anorexia nervosa and bulimia nervosa in the Norwegian National Patient Register (2010-2016). ( 30265747 )
2018
49
Eating Pathology Among Patients With Anorexia Nervosa and Bulimia Nervosa: The Role of Narcissism and Self-Esteem. ( 30273274 )
2018
50
Neuroendocrinology of reward in anorexia nervosa and bulimia nervosa: Beyond leptin and ghrelin. ( 30395874 )
2018

Variations for Bulimia Nervosa

Expression for Bulimia Nervosa

Search GEO for disease gene expression data for Bulimia Nervosa.

Pathways for Bulimia Nervosa

GO Terms for Bulimia Nervosa

Cellular components related to Bulimia Nervosa according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.85 BDNF CCK GHRL LEP NPY PYY
2 dendrite GO:0030425 9.65 BDNF CCK COMT HTR1B HTR2A
3 integral component of postsynaptic membrane GO:0099055 9.5 HTR2A HTR3A SLC6A4
4 integral component of presynaptic membrane GO:0099056 9.26 HTR1B HTR2A HTR3A SLC6A4
5 serotonergic synapse GO:0099154 9.16 HTR1B SLC6A4
6 axon GO:0030424 9.1 BDNF CCK COMT GHRL HTR2A HTR3A

Biological processes related to Bulimia Nervosa according to GeneCards Suite gene sharing:

(show all 27)
# Name GO ID Score Top Affiliating Genes
1 G protein-coupled receptor signaling pathway GO:0007186 9.87 CCK GHRL HTR1B HTR2A MC4R NPY
2 response to drug GO:0042493 9.84 COMT HTR1B HTR2A SLC6A4
3 chemical synaptic transmission GO:0007268 9.76 HTR1B HTR2A HTR3A NPY
4 response to ethanol GO:0045471 9.73 HTR1B HTR3A LEP
5 response to cocaine GO:0042220 9.63 HTR1B HTR3A
6 regulation of signaling receptor activity GO:0010469 9.63 BDNF CCK GHRL LEP NPY PYY
7 G protein-coupled serotonin receptor signaling pathway GO:0098664 9.62 HTR1B HTR2A
8 insulin secretion GO:0030073 9.62 LEP MC4R
9 regulation of sensory perception of pain GO:0051930 9.61 CCK COMT
10 regulation of dopamine secretion GO:0014059 9.61 HTR1B HTR2A
11 G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger GO:0007187 9.61 HTR1B HTR2A NPY
12 activation of phospholipase C activity GO:0007202 9.6 BDNF HTR2A
13 protein kinase C-activating G protein-coupled receptor signaling pathway GO:0007205 9.59 CCK HTR1B
14 eating behavior GO:0042755 9.58 CCK LEP
15 vasoconstriction GO:0042310 9.58 HTR1B SLC6A4
16 energy reserve metabolic process GO:0006112 9.57 LEP MC4R
17 memory GO:0007613 9.56 BDNF CCK HTR2A SLC6A4
18 central nervous system neuron development GO:0021954 9.55 LEP NPY
19 behavior GO:0007610 9.52 HTR1B HTR2A
20 negative regulation of appetite GO:0032099 9.51 CCK LEP
21 negative regulation of synaptic transmission, glutamatergic GO:0051967 9.49 HTR1B HTR2A
22 serotonin receptor signaling pathway GO:0007210 9.48 HTR2A HTR3A
23 regulation of metabolic process GO:0019222 9.4 LEP MC4R
24 positive regulation of appetite GO:0032100 9.37 GHRL NPY
25 adult feeding behavior GO:0008343 9.13 GHRL LEP NPY
26 feeding behavior GO:0007631 8.92 HTR1B MC4R NPY PYY
27 signal transduction GO:0007165 10.1 CCK HTR1B HTR2A HTR3A LEP MC4R

Molecular functions related to Bulimia Nervosa according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 G protein-coupled receptor binding GO:0001664 9.43 GHRL NPY PYY
2 neurotransmitter receptor activity GO:0030594 9.4 HTR1B HTR2A
3 G protein-coupled serotonin receptor activity GO:0004993 9.37 HTR1B HTR2A
4 hormone activity GO:0005179 9.35 CCK GHRL LEP NPY PYY
5 neuropeptide hormone activity GO:0005184 9.33 CCK NPY PYY
6 peptide hormone receptor binding GO:0051428 9.32 CCK LEP
7 serotonin binding GO:0051378 8.92 HTR1B HTR2A HTR3A SLC6A4

Sources for Bulimia Nervosa

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
Content
Loading form....